Literature DB >> 12236424

Present epidemiological pattern of antibody to hepatitis a virus among Chiang Mai children, Northern Thailand.

Prapan Jutavijittum1, Yupa Jiviriyawat, Wanchai Jiviriyawat, Amnat Yousukh, Shigeki Hayashi, Kan Toriyama.   

Abstract

Hepatitis A virus (HAV) infection is common in Southeast Asia, and most of the inhabitants acquire a lifelong immunity as a result of natural infection during childhood. However, the age-specific seroprevalence is changing with development of socioeconomic and hygiene status in this area and the infection is predicted to shift to adulthood with more severe clinical manifestations in the future. In this study, we report the present epidemiological pattern of antibody to HAV (anti-HAV) among schoolchildren in Chiang Mai, Northern Thailand. The overall prevalence rate of anti-HAV was 9.6% (11.4% in female and 7.5% in male children, and 10.8% in urban and 8.9% in rural schoolchildren, respectively). Our study, comparing with previous reports from other parts in Thailand, indicates a steady decline of anti-HAV prevalence among schoolchildren in Chiang Mai area, and discussed a possibility of an outbreak of HAV infection among urban schoolchildren.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12236424

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  2 in total

Review 1.  Hepatitis E virus infection: Epidemiology and treatment implications.

Authors:  Ga Young Lee; Kittiyod Poovorawan; Duangnapa Intharasongkroh; Pattaratida Sa-Nguanmoo; Sompong Vongpunsawad; Chintana Chirathaworn; Yong Poovorawan
Journal:  World J Virol       Date:  2015-11-12

2.  Seroprevalence and incidence of hepatitis A in Southeast Asia: A systematic review.

Authors:  Gustavo Hernandez-Suarez; Debasish Saha; Kris Lodroño; Phatu Boonmahittisut; Stephanus Taniwijaya; Ashwini Saha; Selim Badur; Yong Poovorawan
Journal:  PLoS One       Date:  2021-12-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.